High-throughput MEA-capable organs-on-chip
NETRI introduces the world’s first commercially available MEA-capable organs-on-chip line, NeuroFluidics™ MEA, composed of three compartmentalized microfluidic devices powered by Axion Biosystems’ integrated MEA technology and compatible with Maestro Pro and Maestro Edge systems.
Lyon, France, July 13, 2023 – NETRI today announces the commercial launch of its groundbreaking NeuroFluidics™ MEA line, developed in collaboration with U.S-based biotechnology leader Axion BioSystems and compatible with the company’s flagship Maestro MultiElectrode Array (MEA) systems. A first of its kind, the innovative new product line offers a range of ready-to-use compartmentalized microfluidic devices with an integrated MEA layer, providing high-throughput organs-on-chip platforms for disease research and drug discovery in neurology, dermatology, and other fields.